Agomab reports positive topline data from Stenova extension study of ontunisertib
AGMB•Agomab reported positive topline data from the Stenova open-label extension study of ontunisertib in fibrostenosing Crohn's disease. The company said safety and tolerability were maintained through 60 weeks, while radiological assessment showed a trend toward fibrotic stricture stabilization.
1. Study findings
Agomab reported positive topline data from the Stenova open-label extension study of ontunisertib in fibrostenosing Crohn's disease. The company said the treatment's favorable safety and tolerability profile was maintained through 60 weeks, and radiological assessment showed a trend for fibrotic stricture stabilization.
